Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 4NET 1Endocrine 1

Conditions

Somatostatinoma 1Neurologic Manifestations 1Neuroendocrine Tumors 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Fluorodeoxyglucose F18 3Trastuzumab 2Melphalan 2Magnetic Resonance Spectroscopy 2FAPI-46 2Everolimus 2tipifarnib 1sargramostim 1regorafenib 1lanreotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1exemestane 1entinostat 1cabozantinib 1aldesleukin 1Tirapazamine 1Tamoxifen 1Surveys and Questionnaires 1Sorafenib 1Rose Bengal 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Quality of Life 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Cytidine Triphosphate × Endocrine × Clear all
NCT01163526 2017-01-30

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Stanford University

Terminated
13 enrolled
EndocrineGastrointestinalNET

Colonic Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Neurologic Manifestations, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡